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The effect of oxidants, electrophiles, and NO donors in
rat or human erythrocytes was analyzed to investigate
the influence of protein sulfhydryl groups on the metab-
olism of these thiol reactants. Oxidant-evoked alter-
ations in thiolic homeostasis were significantly differ-
ent in the two models; large amounts of glutathione
protein mixed disulfides were produced in rat but not in
human erythrocytes by treatment with hydroperoxides
or diamide. The disappearance of all forms of glutathi-
one (reduced, disulfide, protein mixed disulfide) was
induced by menadione only in human erythrocytes. The
treatment of rat red blood cells with electrophiles pro-
duced glutathione S-conjugates to a much lower extent
than in human red blood cells; GSH was only minimally
depleted in rat red blood cells. The NO donor S-nitroso-
cysteine induced a rapid transnitrosation reaction with
hemoglobin in rat erythrocytes producing high levels of
S-nitrosohemoglobin; this reaction in human red blood
cells was negligible. All drugs were cleared more rapidly
in rat than in human erythrocytes. Unlike human Hb,
rat hemoglobin contains three families of protein SH
groups; one of these located at position b125 is directly
implicated in the metabolism of thiol reactants. This is
thought to influence significantly the biochemical,
pharmacological, and toxicological effects of some
drugs.
Glutathione is the major low molecular weight thiol in mam-
malian cells where it constitutes the most important antioxi-
dant defense. Its action is usually favored by ubiquitous
enzymes (e.g. glutathione S-transferases, glutathione peroxi-
dase). GSH also regenerates other important defensive re-
sources (e.g. vitamins E and C) and directly participates in the
destruction of reactive oxygen species (1). The alkylation of
glutathione by electrophilic reagents and the reduction of
chemically reactive oxidant species are biological functions as-
sociated with the protection of SH groups of critical cellular
macromolecules (2).
The cell concentration of protein SH groups, ranging from 10
to 30 mM, is larger by far than that of GSH (2–10 mM) (3);
however, the metabolic role against electrophiles and oxidants
is thought to be rather marginal. In fact, the modification of
PSH1 has been usually considered only a potential damaging
reaction, even if some authors suggested that chemical alter-
ation of some cysteine residues may have a protective or regu-
latory role (4, 5).
The participation of PSH in quantitatively important reac-
tions is proportional to their concentration and reactivity. The
intrinsic reactivity of PSH is dependent on the pKa value (the
thiolate anion is much more reactive than the undissociated
form) and its accessibility (structural and conformational fea-
tures). In fact, some proteins such as albumin (6) with rela-
tively low pKa values have an apparent reactivity much lower
than that of GSH. It follows from this that PSH may have a
wide range of apparent reactivity that spans 4 orders of mag-
nitude (7). This fact has abrogated any efforts to understand
the effective defensive contribution of PSH. More recently, the
attention on PSH as important modulators of the intracellular
redox state has been renewed and emphasized (5, 8, 9), and
reports of PSH having reactivity very similar to or greater than
that of GSH are increasing.
Recently, the problem has become more interesting because
a large number of papers have focused on the importance of the
cooperation between GSH and protein SH group, in particular
hemoglobin, in nitric oxide transport, and targeting (10, 11).
Thus, the role of PSH and GSH as similar cooperating groups
in the metabolism of electrophiles, oxidizing agents, and nitric
oxide remains an open question.
Our previous studies have demonstrated that rat hemoglo-
bin possesses reacting cysteines located on the b chain at
position 125 (12). These cysteinyl residues, given their reactiv-
ity and concentration in rat blood, competing and cooperating
with GSH, may influence the pharmacokinetics, toxicity, and
action of many drugs or their metabolites.
To verify whether and by which mechanism, the reactivity of
rat Hb cysteines leads to an unusual metabolism of some thiol
reactants, we analyzed the effect of three different drug cate-
gories, oxidants, electrophiles, and NO donors on human and
rat erythrocytes. Among the oxidants we used were drugs that
react with GSH either enzymatically (via GSH-peroxidase, i.e.
hydroperoxydes) or nonenzymatically (diamide, menadione);
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similarly, electrophiles that conjugate with GSH by glutathi-
one S-transferases catalysis or spontaneously (13) were tested.
The membrane-permeable NO donor S-nitrosocysteine was
also used to evaluate the extent of transnitrosation reactions
carried out by PSH.
EXPERIMENTAL PROCEDURES
Chemicals—Glutathione, glutathione disulfide, and glutathione re-
ductase were obtained from Roche Molecular Biochemicals; HPLC
grade chemicals were from BDH; BCNU was from Bristol-Myers Squibb
(Dublin, Ireland). Diamide (diazenedicarboxylic acid bis(N,N-dimethyl-
amide)), menadione (2-methyl-1,4-naphthoquinone), tert-butyl hy-
droperoxide, human serum albumin, and all other chemicals of analyt-
ical grade were from Sigma.
Blood Collection—Male Wistar rats (2 months old, 300-g body
weight) were purchased from Charles River (Como, Italy). Blood was
collected from the abdominal aorta under anesthesia with diethylether.
Human blood was obtained from healthy volunteers (30–45 years old).
For all blood samples K3EDTA was used as anticoagulant.
Red Blood Cell Treatment—For in vitro treatments each blood sam-
ple was washed with PBS containing 10 mM glucose and was adjusted
to a hematocrit value of 37.5% with the same buffer. Red blood cells
samples were placed in plastic tubes, incubated at 37 °C in a thermo-
static rotating (100 rev/min) bath, and then exposed to the different
substances.
For the in vivo treatment BCNU was infused via PE-50 tubing
cannulated into the femoral vein, whereas blood was collected from a
PE-50 tubing cannulated into the jugular vein. Both tubes were con-
nected to a double valve (model 617, 20 3 20 mm, Danuso Instruments,
Milano, Italy). Valves and tubing were implanted 2 days before the
experiment, under pentobarbital anesthesia (50 mg/kg body weight).
GSH, GSSG, and GSSP Determinations in Blood Samples—Blood
aliquots were deproteinized by the addition of four volumes of 5%
trichloroacetic acid; GSH and GSSG were then determined on the clear
supernatant. GSH was assayed enzymatically, using CDNB and gluta-
thione S-transferases (12); GSSG was assayed enzymatically at 340 nm
by the procedure of Klotzsch and Bergmeyer (14).
To determine GSSP concentrations, acid precipitated proteins were
washed thoroughly with the precipitating solution until no trace of
soluble GSH or GSSG was detected. The pellets were then resuspended
and brought to an alkaline pH (pH 7.5–8.0 for samples of rat red blood
cells and pH 12.0 for the human erythrocytes). The alkaline pH (12.0) is
used in human samples because only under these conditions all mixed
disulfides are released; for rat samples slightly alkaline buffers were
used (pH 7.5–8.0), but similar results are obtained at pH 12.0. Under
these conditions GSH is released via an SH/SS exchange reaction as
previously described by Rossi et al. (15). The amount of released GSH
was assayed enzymatically in the supernatant (see above).
Hemoglobin Preparation—Rat hemoglobin was purified by crystalli-
zation from stroma-free hemolysate by the method of Condo` et al. (16).
Human hemoglobin was prepared using the method of Riggs (17).
Hemoglobin stocks were prepared and maintained under N2. The
amount of oxidized hemoglobin was checked spectrophotometrically
before each experiment on the basis of the 576/541 nm absorbance ratio
(18).
Hemoglobin Sulfhydryls Titration and Determination of the Reactiv-
ity Constants (k2)—PSH of hemoglobin were assayed spectrophoto-
metrically with DTNB at 450 nm (emM 5 7.0 mM
21 cm21): hemoglobin
was adjusted to pH 7.4 with 0.2 M sodium/potassium phosphate buffer,
and then the reaction was started by addition of DTNB (final concen-
tration, 0.2 mM). Fast reacting SH groups were titrated by means of an
Applied Photophysics MV 17 stopped flow apparatus; samples of hemo-
globin in 0.2 M phosphate buffer, pH 7.4, were rapidly mixed with equal
volumes of a solution containing 0.4 mM DTNB in 0.2 M phosphate
buffer, pH 7.4. Data were fitted to a single exponential curve for the
human protein and a three exponential curve for those of rat using the
SigmaPlot, version 2.01 (Jandel Scientific).
Glutathione Reductase Activity—Glutathione reductase activity de-
termination was carried out at room temperature on hemolysate, pre-
viously passed through a Sephadex G-25 column, according to standard
methods (19).
Nitrosothiols—Cys-NO was freshly prepared by combining equimo-
lar concentrations of 200 mM Cys in 0.75 N HCl and 200 mM potassium
nitrite in the presence of 0.1 mM diethylenetriaminepentaacetic acid.
After 3–5 min, the mixture was neutralized with 1 M Tris. Cys-NO and
nitrosoproteins titration was carried out after decomposition of the
S-NO bond with Hg21 and is based on the colorimetric determination of
NO2
2(20).
Glutathione Conjugate and Free Drug Determinations—Glutathione
conjugates and free substances were determined on deproteinized sam-
ples (final concentration, 5% trichloroacetic acid) by HPLC or by spec-
trophotometry. Glutathione-CDNB and glutathione-EA conjugates
were measured by evaluation of the peak at 340 and 290 nm absorb-
ance, respectively; free CDNB and EA were titrated by end point reac-
tions after the addition of glutathione transferases and an excess of
GSH. All other drugs and their adducts with GSH were measured by
HPLC. Briefly, deproteinized samples were loaded onto a Sephasil C18
(250 3 4.6 mm) column (Amersham Pharmacia Biotech) and eluted by
the application of a linear gradient of methanol: 0–10 min 20% meth-
anol 80% acetate buffer (100 mM, pH 4.5), 10–30 min linear gradient
20–100% methanol.
For HPLC determination of glutathione conjugates of BCNU, a Bio-
Rad Biosil NH2 column (250 3 4.6 mm) was used; deproteinized sam-
ples were treated with iodoacetic acid for 45 min ( final concentration,
15 mM) at neutral pH and derivatized with an alcoholic 1.5% solution of
2,4-dinitrofluorobenzene (1:1 for 3 h). Samples were eluted by the
application of a linear gradient of 0.5 M acetate buffer, pH 4.7, after a
10-min isocratic phase (0–10 min with 20% acetate, 80% methanol;
10–30 min with 20–90% acetate). An Hewlett Packard HPLC Series
1100 equipped with diode array detector was used. All spectrophoto-
metric determinations were carried out with a JASCO UV550
apparatus.
RESULTS
Oxidizing Agents—Treatment of human and rat erythrocytes
with oxidizing substances evidenced remarkable differences
between the two species; hydrogen peroxide or organic hy-
droperoxides (tert-butyl hydroperoxide) produced a rapid oxi-
dation of GSH to GSSG (Fig. 1), both in human and rat red
blood cells. However, rat erythrocytes were also characterized
by a subsequent, rapid formation of glutathione-protein mixed
disulfides (GSSP). The initial thiolic homeostasis was com-
pletely restored within 1 h of drug exposure. Diamide (a specific
oxidant for thiol groups) rapidly increased GSSG levels in
human red blood cells; conversely, it produced GSSP but not
GSSG in rat erythrocytes.
Fig. 1 shows the results of the treatment of rat and human
red blood cells with menadione (vitamin K3). Menadione is a
quinone reagent that produces oxidative modifications in bio-
logical systems, mainly through redox cycling reactions with
oxygen (menadione binds to thiol groups to form a conjugate
able to redox cycle like menadione itself) (21). Human red blood
cells were essentially characterized by a rapid GSH disappear-
ance with a negligible (if any) production of GSSG and GSSP.
In contrast, in rat erytrocytes, menadione immediately pro-
duced large amounts of GSSG, which in turn were transformed
into GSSP. In both cases, human and rat red blood cells were
not able to restore initial levels of GSH. Total glutathione (GSH
1 GSSG 1 GSSP) was greatly decreased in human samples,
whereas only a slight decrease was found in rat erythrocytes.
Electrophilic Agents—Glutathione alky(ary)lation by electro-
philic reagents is considered an important metabolic pathway
of many drugs and their intermediates. The formation of these
conjugates is a detoxification reaction because the glutathione-
electrophile adduct is usually less toxic than the parent mole-
cule; after its formation, the conjugate is exported to the extra-
cellular milieu by specific transporters (22). GSH
alky(ary)lation is usually catalyzed by GSH S-transferases, a
ubiquitous class of isoenzymes, which can be divided into four
families (a, m, p, and t encoded by different genes) (23).
Rat and human red blood cells were treated with two known
substrates of GSH S-transferases (CDNB and EA) and with
other reagents that conjugate GSH nonenzymatically (N-eth-
ylmaleimide) or after decomposition into subproducts (BCNU).
After drug addition (1 mM, approximately at a molar ratio of 1:1
with GSH), a rapid increase in intraerythrocytic GSH conju-
gates (Fig. 2A) was detected in all samples, followed by their
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export to the extracellular medium (Fig. 2B). However, remark-
able differences were evident between rat and human red blood
cells. In particular, in the rat, the peak of intraerythrocytic
GSH conjugates was always much lower than that obtained in
human samples; similarly, the amount of exported conjugate
was considerably lower than in human erythrocytes.
In parallel, GSH was almost totally depleted in human
erythrocytes treated with EA, CDNB, BCNU, or N-ethylmale-
imide, but not in rat red blood cells; a percentage varying from
65 to 95% of initial GSH was still present in rat erythrocytes
after 4 h of exposure (Table I).
NO Donors—A large interest in the biochemistry of SH
groups has been stimulated by the discovery that they can have
an active role in nitric oxide metabolism and targeting through
the formation of S-nitrosothiols. These molecules have been
shown to undergo exchange reactions with low and high mo-
lecular weight thiols, reactions of primary importance in the
final effect of nitric oxide itself (24).
In Fig. 3, the influence of a treatment of red blood cells with
S-nitrosocysteine on the levels of intracellular protein S-nitro-
sothiols is shown. S-Nitrosocysteine is a compound able to cross
plasma membranes rapidly and to exchange NO1 group with
other thiols. The kinetics of these reactions are governed by the
reactivity and concentration of various thiol groups. Only slight
variations in S-nitrosoprotein levels were found when human
erythrocytes were used; conversely, under the same conditions
rat red blood cells rapidly produced high levels of
S-nitrosohemoglobin.
Rates of Drug Removal—Among the substances used in the
present work, some are known to be exclusively metabolized (at
least in red blood cells) through conjugation with SH groups,
whereas hydroperoxides (25) and menadione (26) can also react
with Fe21 of the Hb heme group. In Table II the t1⁄2 and the time
required for complete disappearance of free drugs (we did not
consider those metabolized also by heme groups) are reported.
Rat red blood cells removed all substances at a significant
higher rate; within a few minutes (1–5 min) all substances
were in fact under the detection limit, whereas high levels of
FIG. 1. Treatment of human and rat red blood cells with oxi-
dants. Time course of GSH, GSSG, and GSSP in human and rat red
blood cells (37.5% Hct in PBS) after treatment with various oxidants
(final concentration, 2 mM). At specified times aliquots were withdrawn,
and after acid precipitation GSH and GSSG were measured in the clear
supernatant; pellets were analyzed for the GSSP content. S.D. values
were omitted for clarity. The number of replicate experiments was four.
When hydrogen peroxide was used cells were pretreated with 1 mM
NaN3 to inhibit catalase.
FIG. 2. Treatment of human and rat red blood cells with elec-
trophilic agents. Time course of GSH conjugates after treatment of
rat (closed symbols) or human (open symbols) red blood cells (37.5% Hct
in PBS) with 1 mM (final concentrations) of CDNB (M, f), EA (E, l ),
N-ethylmaleimide (, ), and BCNU (L, l) at 37 °C. A, intraerythro-
cytic levels of conjugates. B, extracellular levels of conjugates. At spec-
ified times, red blood cells were pelleted by centrifugation, and proteins
were removed by acidification and centrifugation. In the supernatant,
conjugates were measured by spectrophotometry or HPLC as specified
in methods. S.D. values were omitted for clarity. The number of repli-
cate experiments was 3. BCNU does not react directly with thiols,
thereby in the plot we refer to the 2-chloroethylisocianate (produced by
BCNU decomposition) conjugate with GSH.
TABLE I
GSH concentration in rat or human red blood cells (37.5% Hct in
PBS) after 4 h of treatment with various drugs (1 mM, 37 °C)




No treatment 851 6 84 833 6 101
CDNB 15 6 5 684 6 41
EA 20 6 5 699 6 66
NEM 0 721 6 81
BCNU 44 6 31 789 6 54
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drugs were maintained in human erythrocytes for a long time.
BCNU (the rate-limiting step is given by its spontaneous de-
composition) was metabolized more slowly by both systems;
however, its t1⁄2, as previously reported (27), was half in rat
erythrocytes compared with that in human red blood cells.
Hemoglobin SH Groups—The reactivity of various SH
groups was tested with the common sulfhydryl titrant 5,59
dithio-bis-nitrobenzoic acid. Rat hemoglobin (Fig. 4) was char-
acterized by a rapid reaction when compared with other low
molecular weight thiols or protein cysteines (human Hb, hu-
man serum albumin, GSH, N-acetylcysteine); the shape of the
titration curve is essentially biphasic, showing an initial burst
phase followed by a slower increase in absorbance. The most
important feature is that some rat hemoglobin sulfhydryls,
located at the b125 position (12), are far more reactive than
GSH itself; other cysteines, in positions a13 and b93, are far
less reactive. Titration of these cysteines corresponds to the
slower phase of the curve. Human Hb possesses only one slow
reacting cysteine at position b93 (28). The second order rate
constant (k2) of rat Hb Cys-b125 is about 1 order of magnitude
greater than that of GSH and other low molecular weight thiols
and 3–4 orders of magnitude greater than the k2 of other
protein cysteinyl residues.
Rat and human red blood cells used in previous experiments
(Figs. 2 and 3) were also assayed for Hb-SH content; in Table
III data obtained at the end of the experiment (4 h) are re-
ported. Rat Hb-SH b93 and a13, as well as human Hb-SH b93,
were modified negligibly by the treatments; in contrast, rat
Hb-SH b125 (Table III and Fig. 5) were significantly decreased
(the depletion of Cys-b125 is highlighted by the lower absorb-
ance reached by tracings within 1 s). Depletion of rat Hb
Cys-b125 elicited by drug addition, ranged from 650 to 850 mM
and was consistent with the amount of drug, which was not
found as glutathione conjugate. A dose-dependent depletion of
Hb Cys-b125 was also induced by the oxidants, diamide, tert-
butyl hydroperoxide, hydrogen peroxide, and menadione (data
not shown).
DISCUSSION
Glutathione is commonly considered to be the first line of
defense against oxidizing molecules; it also plays an important
role in the detoxification pathways of electrophilic drugs (29).
Many models show how GSH depletors may initiate irreversi-
ble damage only after a significant decrease (greater than
70–80%) of tissue GSH. The involvement of the SH groups of
proteins in GSH-typical reactions has been regarded as mar-
ginal, in quantitative terms, and as deleterious to protein
structure and function. Even if protein thiols are usually more
concentrated than GSH in cellular pools, their reactivity is
usually 2–4 orders of magnitude lower; this allows GSH to
exhibit its protective role (30). The catalysis of a wide number
of conjugation reactions by glutathione transferases provides a
further protection of protein SH groups by GSH (2).
The reaction rate of small thiols (i.e. N-acetylcysteine, cys-
teine, or glutathione) with titrating molecules is usually well
correlated with the pKa of the sulfydryl group (which normally
lies between pH 8.5 and 9.5). However, for PSH, accessibility as
well as the dissociation state of the sulfur must be considered
(3). Various protein SH groups have been identified as “fast
reacting,” for example, SH of cysteine proteases (papain) (31),
or SH involved in the catalysis of glycolytic reactions (glycer-
aldehyde-3-phosphate dehydrogenase) (32); however, their
overall quantitative contribution to the metabolism of electro-
philes or oxidants is clearly marginal.
Blood is characterized by the presence of high concentrations
of Hb (8–10 mM, as monomer), a value significantly larger than
GSH (0.8–1 mM). It is well known that human Hb has only one
titrable pair of thiols per tetramer (Cys(F9)93b) and that its
reactivity is also dependent on the quaternary conformation,
being slower in the deoxy state (10). Cys-b93 of human Hb is
shielded by a hydrogen bond between Asp-94 and Glu-90 (28)
and is also influenced by the vicinity of the terminal carboxyl
group.
Rat hemoglobin is known to possess extra reactive SH groups
compared with human Hb; cysteines located at b125 and a13
(33) positions were identified as additional potentially reactive
cysteinyl groups. Cysteine b125 was shown to have a low pKa,
a high accessibility, and consequently a strong reactivity (12).
Moreover, its reactivity is not influenced by allosteric changes
in the protein. This low pK is due to a hydrogen bridge between
SH of Cys-b125 and Ser-123, where SH is the hydrogen donor.
Comparison (Fig. 4) of the reaction kinetics of various SH
groups with DTNB demonstrated how rat Hb is essentially
characterized by two different families of thiols. One family has
a reaction rate 1 and 3 orders of magnitude greater than small
thiols and other protein thiols (e.g. human Hb Cys-b93),
respectively.
This has proved the existence of thiols on rat Hb possessing
an unusually high reactivity. The task is now to verify whether
this anomaly can in any way influence the overall metabolism
of some agents.
Usually, treatment with oxidizing agents (e.g. organic hy-
droperoxides) leads to the oxidation of GSH into GSSG. After
drug reduction, the system recovers the initial levels of GSH. If
the oxidative stress is severe, a SH-SS exchange reaction be-
tween GSSG and PSH can take place (34, 35) to form protein
glutathione mixed disulfides. This reaction is more effective in
the presence of highly reactive SH groups (34).
From the data shown in Fig. 1, it can be readily deduced how
rat red blood cells, by means of fast reactive Hb thiols, are able
to form large amounts of GSSP; in contrast, only GSSG is
generated in human erythrocytes. The differences between the
two species are more evident when diamide or menadione are
used. In the first case, GSSP, but not GSSG, were produced by
FIG. 3. Treatment of human and rat red blood cells with Cys-
NO. Rat (E) and human (f) red blood cells (37.5% Hct in PBS) were
treated with Cys-NO (final concentration, 1 mM) at 37 °C. At specified
times, cells were pelleted by centrifugation and hemolyzed by the ad-
dition of 10 volumes of water; the samples were then passed through
G25 columns, and nitrosothiols were measured on the protein fraction.
The number of replicate experiments was three.
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rat red blood cells. This was due to the rapid reaction of dia-
mide with Cys-b125 of rat Hb to form an intermediate, which is
then cleaved by a molecule of GSH to form mixed disulfide with
hemoglobin (36). The irreversible GSSP production in rat red
blood cells after diamide treatment is likely to be due to the
trapping of all available GSH into GSSP; in fact, the reduction
of protein mixed disulfides is catalyzed by thioltransferase,
which needs GSH as a cofactor (37).
Menadione-evoked alterations of GSH are rather complex.
Because this drug is able both to oxidize and conjugate, the
interpretation of its overall action is not easy. The negligible
production of GSSG and GSSP in human red blood cells and, in
contrast, the generation of both GSSG and GSSP in rat red
blood cells, after menadione treatment, can be interpreted in
the light of the presence of fast reacting SH in the rat. Mena-
dione is likely transformed into semiquinone by reaction with
Fe21 of Hb (26); the semiquinone is probably an electrophile
stronger than menadione itself and rapidly conjugates with
GSH. This may explain the disappearance of all forms of GSH
in human red blood cells (reduced, disulfide, mixed disulfide).
On the other hand, rat hemoglobin can intercept the semiqui-
none by its Cys-b125. The thiolic conjugates of menadione are
known to redox cycle (38) (like menadione itself), and this is
evident by subsequent oxidation of GSH in rat red blood cells.
We can also speculate that the conjugate of menadione with
Cys-b125 can redox cycle more efficiently than the GSH men-
adione adduct.
The conjugation activity of rat Hb toward electrophiles is
also demonstrated in Fig. 2; in all time courses of human
erythrocytes, a rapid formation of glutathione conjugates is
evident, followed by its export to the extracellular milieu. Rat
erythrocytes metabolized the drugs by GSH conjugation to a
remarkably lower extent; in fact, both intracellular and extra-
cellular levels of conjugates were far lower than that of the
corresponding human samples.
In addition, GSH levels were close to 0 in all human red blood
cells samples after treatments, whereas in rat erythrocytes
most of the GSH was preserved (Table I). Rat erythrocytes
usually quickly metabolized all compounds (Table II) unlike
human red blood cells (high levels of free drug persisted for
minutes to hours). Our data suggest that rat Hb can play a role
in the metabolism of such substances by its fast reacting Cys-
b125 (Table III and Fig. 5) with a possible influence on the
biochemical, pharmacological, and/or toxicological activity of
many drugs.
An example confirming this hypothesis can be obtained by
data on BCNU (Fig. 6). BCNU is a cytostatic drug that belongs
to the group of DNA alkylating and cross-linking agents (39).
Additional mechanisms of BCNU action have been proposed
(27), notably the inhibition of glutathione reductase. This fur-
ther mechanism of action is considered to contribute both to the
desired effects and the toxicity of the drug (27). Erythrocyte GR
activity has been shown to be reduced to 10% of the initial
value in patients 10–30 min after BCNU administration (40).
After incubation with BCNU (dose range, 2–200 mM), the
residual activity of GR showed little variations in rat red blood
cells even when high concentrations of BCNU were used. In
contrast, a dramatic decrease was observed in human erythro-
cytes. The inhibition is due to the binding of the BCNU decom-
position product, 2-chloroethylisocianate, to the SH group of
the catalytic site of glutathione reductase (27). Rat Hb can
intercept this molecule (via Cys-b125), thus protecting GR from
inhibition (IC50 values were 350 6 25 and 5.5 6 2.0 mM for rat
and human red blood cells, respectively). Furthermore, the in
vivo treatment of the rat with BCNU leads to minimal, if any,
changes in GR activity. Even if higher doses than that gener-
ally used for chemotherapy (which was shown to inhibit GR up
to 90% hematic GR) (40) were administered to rats (Fig. 6B), no
variations in rat hematic GR were found.
Nitric oxide is a signaling molecule that has captured much
the attention of researchers. NO has a short half-life in vivo
and the existence of more stable transport forms of NO has
been postulated (41). NO and NO derived species (NOx) can
react with protein and nonprotein thiols forming nitrosothiols.
S-nitroso derivatives of glutathione, cysteine, hemoglobin, bo-
vine serum albumin, and other protein or nonprotein thiols are
potent, fast acting vasodilators as well as strong inhibitors of
platelet aggregation (24). Stamler and co-workers (10, 11) re-
ported that Hb can act either as a sink or as a donor of nitric
TABLE II
Half-life and time required for complete removal of various drugs (diamide, 2 mM; all other drugs, 1 mM; 37 °C) in rat or human red blood cells
(37.5% Hct in PBS)
The number of replicate experiments was 4.
t1/2 Time required for complete removal
Human Rat Human Rat
Diamide 10 min ,30 s 30 min ,30 s
CDNB 20 min ,30 s 2 h 3 min
EA 25 min ,30 s 2 h 4 min
NEM 1 min ,30 s 2 min ,30 s
BCNU 1 h 30 min .4 h 3.5 h
Cys-NO 45 min 2 min 2.5 h 5 min
FIG. 4. Titration of various SH with DTNB. Thiols (hemoglobins,
10 mM; albumin, 20 mM; GSH and N-acetylcysteine, 10 mM) in 0.2 M
phosphate buffer, pH 7.4, were titrated with DTNB (final concentration,
0.2 mM) at 25 °C. A, rat hemoglobin; B, GSH; C, N-acetylcysteine; D,
human serum albumin; E, human hemoglobin.
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oxide depending upon its quaternary state, with a pivotal role
in the regulation of blood vessel tone. In these reports they
suggest that exchange reactions between low molecular weight
nitrosothiols and SH groups of Hb play an important role in
mediating nitric oxide effects in the bloodstream. In describing
their model, the authors pointed out that Cys-b93 of human Hb
is involved in red blood cells nitric oxide handling and that a
rapid exchange reaction between S-nitrosocysteine and Hb-SH
groups takes place. In some experiments however, rat instead
of human red blood cells were used. Our data demonstrated
that fundamental differences exist among the two systems,
with only rat Hb being rapidly nitrosylated. After treatment
with S-nitrosocysteine (Fig. 3) the intracellular levels of S-
nitroso hemoglobin rose rapidly in rat red blood cells (0.22 NO
mol/mol tetramer of Hb, after 2 min), whereas minimal varia-
tion was found in human erythrocytes (0.007 NO mol/mol tet-
ramer of Hb, after 5 min); the use of rat instead of human blood
could lead thereby to some misinterpretation of results repre-
senting a poor and irrilevant model as to human studies.
In conclusion, data obtained from our work suggest that
when the rat is used as an animal model, some attention must
be paid to the unusual behavior of its Hb-SH groups. Because
of the reactivity of these cysteinyl residues, the rat is an inter-
esting but complicated model in which to study the pharmaco-
logical and toxicological action of some drugs. The fact that rat
Hb possesses six reactive cysteines/tetramer, makes rat blood
per se a bad model for some biochemical/physiological interpre-
tations (i.e. nitrosothiols action). Furthermore, if we consider
that cys b125 is extremely reactive (about 3 orders of magni-
tude greater than human b93), this makes rat red blood cells
able to metabolize some thiol-reacting substances mainly
through conjugation/oxidation of its cysteine b125.
Wistar strain male rats were used for all the experiments
reported in this work; however, also other strains of rat (e.g.
Harlan, Sprague-Dawley) behave similarly (not shown). Also
rats of different ages and body weights were studied (age, 6–9
months; body weight, 450–550 g), but only slight differences in
the metabolism of thiol reactants were found (not shown).
It is well known that some drugs (i.e. acetaminophen,
ethacrynic acid, and dapsone) (42–44) have different modes of
action in rat and man, in terms of dose response curves and
toxic limit concentrations; it is thereby possible that as these
compounds are able to react with SH groups, such differences
can be due (at least in part) to the presence of high reacting
thiols on rat Hb. Because the rat is widely used as a model to
study the hemotoxicity of xenobiotics, we consider that our
results pose an important question and can help to clarify some
aspects of metabolism of thiol reactants by rat and human
blood.
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